Cargando…
Noninvasive biomarkers for lung cancer diagnosis, where do we stand?
The 2010’s saw demonstration of the power of lung cancer screening to reduce mortality. However, with implementation of lung cancer screening comes the challenge of diagnosing millions of lung nodules every year. When compared to other cancers with widespread screening strategies (breast, colorectal...
Autores principales: | Kammer, Michael N., Massion, Pierre P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330751/ https://www.ncbi.nlm.nih.gov/pubmed/32642255 http://dx.doi.org/10.21037/jtd-2019-ndt-10 |
Ejemplares similares
-
Do we need to see to believe?—radiomics for lung nodule classification and lung cancer risk stratification
por: Khawaja, Ali, et al.
Publicado: (2020) -
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
por: Silvestri, Gerard A., et al.
Publicado: (2018) -
Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019) -
Evaluating the efficacy of bronchoscopy for the diagnosis of early stage lung cancer
por: DiBardino, David M., et al.
Publicado: (2020) -
Reducing uncertainty to a manageable level: the need for a nuanced and patient-centric approach to lung nodule management in the 21(st) century
por: Maldonado, Fabien, et al.
Publicado: (2020)